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Pouchitis is a common complication that develops after an ileal pouch-anal anastomosis after colectomy for ulcerative colitis.
In some cases, pouchitis becomes chronic and refractory to conventional therapies including antibiotics, corticosteroids,
immunomodulators,probiotics, and anti-inﬂammatory drugs. We report a case of an adolescent with chronic pouchitis who not
onlyimproved with inﬂiximabtherapy but remains in long-term remissionwith maintenancetherapy without any adverse eﬀects.
Inﬂiximab is a safe and eﬀective therapy for refractory pouchitis and may obviate the need for pouch removal and a permanent
ileostomy.
1.Introduction
Approximately one-third of patients with ulcerative colitis
will require a colectomy as a result of medically refractory
disease,adverse sideeﬀectsfromtherapy,orthedevelopment
of dysplasia [1]. With surgical advancements, most patients
who require colectomy are able to avoid a permanent stoma
as a result of ileal pouch-anal anastomosis (IPAA). However,
up to 60% of patients who undergo IPAA will develop pou-
chitis,anidiopathicinﬂammation oftheileal-analpouch[2].
Pouchitis can present with a variety of symptoms including
abdominal pain, diarrhea with or without blood, urgency,
fecal incontinence, and weight loss [3]. In many instances,
the pouchitis is mild and resolves after medical therapy;
however, in 5–10% of cases, the pouchitis becomes chronic
and a small subset of these patients develop refractory
pouchitis which may require ileal-anal pouch removal and
a permanent ileostomy [2].
Inﬂiximab (antitumor necrosis factor alpha monoclonal
antibody) is an eﬀective therapy for Crohn’s disease and
acute ulcerative colitis. However, its use in chronic refractory
pouchitis has rarely been described. We report a case
of successful induction and long-term maintenance of
remission of chronic, refractory pouchitis with inﬂiximab in
an adolescent.
2.Case Report
The patient was diagnosed with severe ulcerative pancolitis
at the age of 8 years after presenting with bloody diarrhea,
abdominal pain, and weight loss. She was treated with
various combinations of corticosteroids, azathioprine, sul-
fasalazine, and oral mesalamine. Adequate remission could
not be maintained, and the patient had several admissions to
the hospital over the next two years. After failure of medical
therapy, a total colectomy and temporary ileostomy were
performed at the age ten years, followed by an IPAA ﬁve
months later.
One month following her IPAA, the patient developed
abdominal pain, severe diarrhea with urgency and incon-
tinence, and weight loss. A clinical diagnosis of pouchitis
was made, and a course of metronidazole was administered.
The patient had a very stormy course with severe diarrhea,
often with blood, nocturnal stool incontinence, abdomi-
nal pain, and weight loss. She was treated with various
combinations of metronidazole, ciproﬂoxacin, mesalamine2 Gastroenterology Research and Practice
(systemic and local), steroids (systemic and local), and
loperamide. Endoscopy of the pouch showed patchy ery-
thema, and biopsies revealed mild nonspeciﬁc chronic and
acute inﬂammation but no granulomas. Another course of
metronidazole and ciproﬂoxacin improved her symptoms,
but every attempt to discontinue either of the antibiotics led
to an exacerbation in the symptoms.
Another endoscopy a year later showed focal ulcers with
surrounding erythema. The histology revealed increase in
acute and chronic inﬂammatory cells, cryptitis, and crypt
abscesses. Her symptoms continued to ﬂuctuate despite
treatment with various combinations of antibiotics, sul-
fasalazine, mesalamine enemas, corticosteroids, a probiotic
formulation (VSL no. 3), 6-mercaptopurine, and bowel
rest with total parenteral nutrition. Another endoscopic
examination two years later revealed small ulcerations
throughout the pouch and biopsies conﬁrming acute and
chronic inﬂammation. After another severe exacerbation a
year later, the pouch was found to be grossly inﬂamed
with diﬀuse ulcerations (Figure 1(a)). The biopsies showed
mild to moderate active chronic inﬂammation, cryptitis, and
crypt abscesses without any granulomas (Figures 1(b) and
1(c)).
Crohn’s disease wascarefully excludedafterre-evaluation
of her history, re-examination of the original procto-
colectomy specimen, and examination of the proximal
gastrointestinal tract with endoscopy and biopsies. There
was no evidence of ﬁstula, clinically or on investigations
including barium small bowel study and abdominal com-
puterized tomography. The serology was negative for anti-
Saccharomyces cerevisiae antibody (ASCA) and positive for
perinuclear antineutrophil cytoplasmicantibody (p-ANCA).
Stools were repeatedly negative for pathogens including
Clostridium diﬃcile.
After failure of all medical therapies over seven years,
the patient was administered inﬂiximab (5mg/kg) at 0,
2, and 6 weeks. The 6-mercaptopurine (1.5mg/kg/day)
was continued. The patient had a dramatic response with
immediate relief of symptoms and improved weight gain.
Therapy was continued with inﬂiximab administered
every 8 weeks. The 6-mercaptopurine was discontinued a
year later. The patient continues to remain in complete
remission 36 months after initiating inﬂiximab with reg-
ular infusion of 5mg/kg every 7 weeks. The most recent
endoscopy of the pouch (after two years of inﬂiximab
therapy) revealed completely normal mucosa with no
inﬂammation (Figures 2(a) and 2(b)). The patient did not
experienceany adverse eﬀectsthroughoutthetreatment with
inﬂiximab.
3.Discussion
The etiology of pouchitis remains unclear. One hypothesis
is that pouchitis occurs as a consequence of dysbiosis of
the microbial ﬂora within the pouch; therefore, antibiotics
are typically the ﬁrst-line treatment with the hope of
eradicating the dysbiotic ﬂora and restoration of normal
ﬂora [4]. Most patients respond to a short course of
(a)
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Figure 1: (a) Endoscopic appearance of the ileal pouch before
starting inﬂiximab therapy showing diﬀuse inﬂammation. (b)
Histology of the ileal pouch before starting inﬂiximab therapy
showing focal moderate ulceration and cryptitis with a crypt
abscess. (c) Histology of the ileal pouch before starting inﬂiximab
therapy showing focal chronic regenerative glandular changes.
ciproﬂoxacin or metronidazole although up to 60% of
patients will develop a second episode of pouchitis and
5–10% will require long-term antibiotic treatment [5]. A
variety of other therapies have also been tried either alone
or in combination including probiotics, budesonide (sys-
temic or local), prednisone, mesalamine (systemic or local),
immunomodulators (6-mercaptopurine, azathioprine, and
cyclosporine), and octreotide [2, 6–9]. Response to anti-
inﬂammatory and immunomodulator therapies implies thatGastroenterology Research and Practice 3
(a)
(b)
Figure2:(a)Normalendoscopicappearanceoftheilealpouch after
inﬂiximab therapy. (b) Normal histology of the ileal pouch after
inﬂiximab therapy.
cytokines including tumor necrosis factor-alpha likely play a
role in the maintenance of pouchitis.
A report by Molnar et al. recently described the use of
inﬂiximab in the treatment of a 16-year-old girl with severe
refractory ﬁstulizing pouchitis [10]. Within 4 weeks of total
colectomy and IPAA, the patient developed severe ﬁstulizing
pouchitis unresponsive to medical therapy. A temporary
ileal diversion was performed which resulted in complete
symptom relief. However, after reconstruction, severe pou-
chitis developed six weeks later. Antibiotics, topical budes-
onide, oral corticosteroid, and azathioprine therapy were all
unsuccessful. Within receiving three infusions of inﬂiximab
(5mg/kg), the patient became completely asymptomatic,
and remission of her pouchitis was proven by endoscopy
and histology. The patient was maintained in remission
with regular infusions of inﬂiximab every 8 weeks for 16
months. A ﬁstulizing lesion in a patient in inﬂammatory
bowel disease always raises the question of the underlying
disorder being Crohn’s disease. As this patient developed
ﬁstulizing pouchitis, it is unclear how Crohn’s disease was
excluded as a possibility in this patient [10].
Viscido et al. studied the use of inﬂiximab in seven adult
patients, mean age 32 years (range 19–51), with chronic
refractory ﬁstulizing pouchitis [11]. To exclude Crohn’s
disease, the researchers re-examined the patient’s history,
proctocolectomy specimen, and small intestine. Inﬂiximab
infusions (5mg/kg) were given to all seven patients at 0,
2, and 6 weeks. Azathioprine was given as a bridge treat-
ment. At 10 weeks, six out of seven patients had a com-
plete clinical response, while the remaining patient had a
partial response. Five out of seven patients had complete
ﬁstula closure, while the remaining two had partial closure.
Patients also experienced complete remission from their
extraintestinal manifestations, including erythema nodosum
and arthralgia, after the ﬁrst infusion of inﬂiximab. At ﬁnal
followup, (median 35 months, range 31–57)and with several
infusions (mean 4, range 3–7), six out of seven patients
were still in complete remission. However, the patient who
only had a partial response at the 10-week followup was
now in remission, while a patient who had complete clinical
remission had recurrence of the pouchitis and ﬁstula. The
only adverse eﬀect observed was thoracic herpes simplex
infection in one patient which was successfully treated with
acyclovir. The investigators concluded that inﬂiximab plus
azathioprine is a safe and eﬃcacious treatment of chronic
refractory pouchitis complicated by ﬁstulae.
Calabreseetal.dida short-term, singleblind,prospective
cohort study looking at the use of inﬂiximab in chronic
refractory pouchitis complicated by ileitis [12]. Ten patients,
mean age 39 years (range 23–56), were treated with inﬂix-
imab (5mg/kg) at 0, 2, and 6 weeks. Pouch endoscopy and
capsule endoscopic assessment were done at 10 weeks, and
clinic assessments at 6, 12, 24, and 48 weeks. Nine out
of ten patients had clinical remission, while eight of these
patients also developed complete macroscopic remission.
One patient without clinical remission did show endoscopic
improvement while the last patient did not show any clinical
or endoscopic improvement. The same eight patients in
remission at 10 weeks were maintained in remission for a
minimum of six months (range 8–16 months). There were
no signiﬁcant adverse eﬀects reported.
More recently, a study investigated the use of inﬂiximab
in 28 IPAA patients for refractory luminal inﬂammation
(pouchitis and/or prepouch ileitis) and/or pouch ﬁstula
[13]. The majority of patients were concomitantly treated
with immunomodulatory agents. After ten weeks of starting
inﬂiximab, 8 patients with refractory luminal inﬂammation
showed complete clinical response and 3 showed complete
ﬁstula response. Of those who responded partially or com-
pletely, 56% had a sustained clinical response. Five patients
needed a permanent ileostomy.
Inﬂammatory bowel disease encompasses two distinct
disorders, ulcerative colitis and Crohn’s disease. The diag-
nosis of these disorders is based on clinical, biochemical,
radiological, endoscopic,and histological features, as there is
no single test to conﬁrm the diagnosis. The development of
chronicpouchitisinapatientwithulcerativecolitisandIPAA
always raises the concern that the underlying disorder could
be Crohn’s disease. Therefore, it is imperative that Crohn’s
disease be carefully excluded in such cases. It is possible that
some patients reported in the above-mentioned studies had
Crohn’s disease as the underlying disorder. Inﬂiximab has
been used eﬀectively for treatment of Crohn’s disease of the
ileoanal pouch [14]. Our patient did not have any evidence4 Gastroenterology Research and Practice
of Crohn’s disease or ﬁstula and is also unique in terms of
the longest reported duration of therapy with inﬂiximab in
pouchitis in an adolescent.
In conclusion, inﬂiximab is a safe and eﬀective ther-
apy for refractory pouchitis in adolescents who have had
colectomy and IPAA for ulcerative colitis. It is also eﬀective
in maintaining long-term remission, hence avoiding the
need for pouch removal and a permanent ileostomy. A
randomized controlled trial is needed to further assess the
eﬃcacy of inﬂiximab in the treatment of chronic refractory
pouchitis.
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